EDAP Edap Tms S.A. ADS

EDAP to Participate in the 2024 Jefferies London Healthcare Conference

EDAP to Participate in the 2024 Jefferies London Healthcare Conference

         

LYON, France, November 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and host 1x1 investor meetings at the Jefferies London Healthcare Conference, which is being held November 19-21, 2024.

Date:              Tuesday, November 19

Time:              8:30-8:55 AM GMT

Location:         The Waldorf Hilton London

Webcast:         

The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website .

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit ,  and .

Company Contact

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

50

Investor Contact

John Fraunces

LifeSci Advisors, LLC

(917) 355-2395



EN
06/11/2024

Underlying

EDAPEdap Tms S.A. ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edap Tms S.A. ADS

Free Trial
EDAP Edap Tms S.A. A...

EDAP TMS S A : 1 director

A director at EDAP TMS S A sold 9,900 shares at 2.578USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

EDAP EDAP TMS S.A. ADS
6h / 6m 6h / 6m 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP Reports Third Quarter 2024 Financial Results

EDAP Reports Third Quarter 2024 Financial Results          Reported Q3 worldwide revenue of EUR 13.1 million (USD 14.4 million), increasing 11.6% over Q3 2023Reported Q3 worldwide HIFU revenue of EUR 4.5 million (USD 4.9 million), increasing 48.2% over Q3 202334% year-over-year growth in U.S. Focal One HIFU procedures CMS increases Medicare Hospital Outpatient Focal One HIFU procedure payment by 5.4% for 2025Announced AI collaboration with Avenda Health for Focal One Robotic HIFUCompany to host conference call and webcast today, November 7th, at 8:30 a.m. EDT LYON, France, November 7, ...

November 7, 2024 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP to Participate in the 2024 Jefferies London Healthcare Conference

EDAP to Participate in the 2024 Jefferies London Healthcare Conference           LYON, France, November 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and host 1x1 investor meetings at the Jefferies London Healthcare Conference, which is being held November 19-21, 2024. Date:              Tuesday, November 19 Time:              8:30-8:55 AM GMT Location:         The Waldorf Hilton London Webcast:          The live and archived webcast of ...

November 6, 2024 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2...

EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2024 Company to host conference call and webcast on Thursday, November 7th at 8:30am EDT LYON, France, October 24, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2024, before the markets open on Thursday, November 7th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, a...

October 24, 2024 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP Announces First Patients Treated in Phase I/II Study Evaluating F...

EDAP Announces First Patients Treated in Phase I/II Study Evaluating Focal One Robotic HIFU for the Treatment of Benign Prostatic Hyperplasia (BPH)          LYON, France, October 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study evaluating the Company’s proprietary Focal One® robotic high-intensity focused ultrasound (HIFU) technology for the treatment of benign prostatic hyperplasia (BPH). “We’ve been offering targeted HIFU ablation to prostate cancer patients for ...

October 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch